Patent

This Year

From the program: IP Issues in Business Transactions 2013

Released on: Mar. 12, 2013

This comprehensive program will provide an in-depth understanding of intellectual property issues that arise in corporate transactions, including the strategic role of intellectual property in a company and the many unique considerations that come into play. Learn how to assess intellectual property as a strategic asset and how to evaluate opportunities to monetize IP while avoiding costly missteps. Other essential topics addressed include IP portfolio ...

Published: January 2013

Recorded on: Jan. 24, 2013

Taken from the briefing America Invents Act Pro Bono Program for Inventors and Small Businesses recorded January, 2013. The America Invents Act (AIA) requires that the Director of the United States Patent and Trademark Office (USPTO) work with local intellectual property (IP) organizations across the country in establishing pro bono patent  services for inventors and small businesses. Since the passage of this bill, four pro ...

From the program: Advanced Licensing Agreements 2013

Released on: Apr. 4, 2013

Licensing transactions are more complex than ever. The constantly evolving legal, regulatory and technical landscape drives the need to stay current in all of these key areas. Whether utilized to develop technology, expand or create market opportunities, or generate returns from existing assets, managing complex licensing transactions requires a broad and varied toolkit. Additionally, whether licensing patents, copyrights, trade secrets or trademarks, ...

From the program: IP Enforcement and Litigation 2013: Criminal and Civil Update

Recorded on: Feb. 12, 2013

Taken from the Web Program IP Enforcement and Litigation 2013: Criminal and Civil Update recorded February, 2013 in New York. Lecture Topics  [01:02:00] Patent Enforcement Update  [01:02:00] The impact of new patent legislation on patent litigation Patent case law trends When and how to use ITC proceedings for patent or other IP enforcement Update on Proposed Amendments to ITC Rules of Practice and Procedure The ...

From the program: Patent Law Institute (7th Annual)

Released on: Apr. 2, 2013

The Institute is designed to be of ultimate practice value to all three subgroups in the patent law community: patent prosecutors, patent litigators, and strategic/transactional lawyers.Do not miss this unique opportunity to sharpen your practice skills and network with federal judges, USPTO officials, in-house counsel and outside patent lawyers.Lecture Topics  [Total time 12:46:15] Segments with an asterisk (*) are available only with the purchase ...

• Sep. 18 - 22, 2013 New York, NY
• Nov. 20 - 24, 2013 San Francisco, CA

Anyone with a degree in science or engineering (or sometimes, the equivalent) can take the Patent Bar Exam to become a patent agent or patent attorney. Patent law is a field of challenging and ever-changing opportunities. Be at the forefront of innovation . . . lead at  the forefront of innovation. PLI’s now-proven steps to success on the Exam: Unique, interactive, diagnostic software that replicates what you’re going ...

From the program: USPTO Post-Grant Patent Trials 2013

Released on: Apr. 10, 2013

Post-grant patent proceedings were pursued in record number at the USPTO in 2012. The substantial costs and uncertainty of patent litigation require the development of alternative case management strategies, which at least require consideration of challenging patents at the USPTO. To this end, patent reexamination remains a viable alternative to costly litigation or parallel path to enhance litigation positions. Yet due to the public outcry for even ...

Recorded on: Mar. 8, 2013

Taken from the briefing USPTO First-to-File Implementation Guidelines: What They Say and What They Meanrecorded March, 2013. The USPTO has now finalized their approach to the role out of First-to-File. Find out the details and learn some of the wrinkles that may be resolved only once the CAFC has had a chance to have their say. It is a place to start, but where do we go from here, and can we obtain some insight on the approach the CAFC might ...

Recorded on: Mar. 19, 2013

DOUGLAS R. NEMEC: So we'll moving into developments in pharmaceutical and biotech patent litigation, a topic that's of interest, I think, to a narrower group of the audience than perhaps some that we've been covering. But to those of us who practice in that area, it's an area of great interest and one where there's really a lot going on in recent months and recent years. I'm happy to turn the program over to Asim Bhansali, who's a partner at Keker ...

Recorded on: Mar. 19, 2013

[? DOUGLAS R. NEMEC: Brian ?] managed to cover about 800 pages of Federal Register reports on Patent Office rule-making. We'll now turn it over to Denise De Mory to cover 800 or more pages of court decisions from the last year from Supreme Court, Federal Circuit, and other courts. You've got a challenge on your hands there. Denise is a founding partner at Bunsow, De Mory, Smith, and Allison in Silicon Valley. She's got about 20 years of experience ...

Recorded on: Mar. 20, 2013

SPEAKER 1: OK, we're going to go ahead and get restarted. Welcome back, everyone. We are here at the Patent Markets panel. A lot has been happening, as most of you know, with relation to patents, and buying and selling and brokering of them, as of late. We're fortunate to have several people here today, very knowledgeable this area, to talk to us about some of these issues. To my immediate right, your left, is Kevin Barhydt, who is Vice President ...

Recorded on: Mar. 20, 2013

DOUGLAS NEMEC: Welcome back, everybody. We'll get started with the first plenary session of the day. We're going to spend the next hour talking about litigation involving non-practicing entities, or patent-assertion entities, or patent trolls-- whatever term you prefer. When I started practicing-- it really wasn't all that long ago, in the 1990s-- these terms really didn't exist. Patent troll was a really unattractive patent lawyer, and a non-practicing ...

Recorded on: Mar. 20, 2013

SCOTT ATLER: All right. We're gonna go right into the next session which is gonna be hot topics in technology transfer. We have a couple of great speakers to talk to us about this topic today. The first is Cheryl-- CHERYL FRAGIADAKIS: Thank you. SCOTT ATLER: --Fragiadakis who is head of technology transfer and intellectual property management at the Lawrence Berkeley National Laboratory. That lab is the oldest US national laboratory operated for ...

Recorded on: Mar. 20, 2013

JOHN WHITE: Hello, welcome back. It's time for our last hour together. That's right, we're here. I know, sadness, because it's almost over. And there's nothing like two days of patent fun bringing us all together. So I have a few things. Number one, thank you all for coming. And the thing we want back from you are your evaluations. This can be accomplished on those iPads in front of you. And there are two tabs, one for faculty and one for content. ...

Recorded on: Mar. 20, 2013

SCOTT ALTER: So to keep things on time, we're gonna go ahead and get started. This is the corporate counsel panel also known as what keeps corporate in-house counsel up at night. And for that we have some outstanding corporate counsel to talk about these issues with us. Too close. Stay a little bit away from the microphone, I'm told here. Our first panelist is T. J. Angioletti who is Associate General Counsel, Technology Transactions for Netflix. ...

From the program: Developments in Pharmaceutical and Biotech Patent Law 2013

Released on: Apr. 15, 2013

Pharmaceutical and biotech patent law is an important and rapidly changing practice area, and the program is designed to give you the information you need to maintain your practice edge, concentrating on new developments from 2012 and placing them in the context of constantly evolving areas of the law.Technological innovation, Federal Circuit appellate oversight, and Supreme Court decisions continue to drive significant changes in the law. Several ...

Recorded on: Apr. 2, 2013

DAVID K. BARR: Switch to our second topic which is biologic and biosimilar drug products. And I'm fortunate to have with me sharing this topic, Betty Ryberg. And introducing Betty Ryberg, she joined Novartis in 2008 as vice president of US IP litigation for group intellectual property. And she leads Novartis Corporation's IP group. Before joining Novartis, Betty was a colleague of ours at Kaye Scholer. And she worked on numerous pharmaceutical biotech ...

Recorded on: Apr. 2, 2013

DANIEL L. REISNER: Morning, everyone. I'm going to start with the first topic of the day, which is claim construction. Judge Holderman, about five years ago, wrote, something has to change when your boss, upon reviewing your work, continues to tell you, year after year, that you are doing your job incorrectly about 1/3 to 1/2 of the time, and your customers continue to tell you their costs are too high. Judge Holderman was speaking about the Federal ...

Recorded on: Apr. 2, 2013

DAVID BARR: Everyone just a brief change in our schedule. We're going to be going forward with the in-house panel on pharma and biotech litigation for the 3:00 slot. And the panel on biotech and pharma licensing in Asia will take place at 4:00. So same subject matter, just flipping those two panels. So we're pleased and privileged to have today with us three in-house counsel to discuss a lot of the issues-- maybe in more depth than we were discussing ...

Recorded on: Apr. 2, 2013

DANIEL L. REISNER: It's my pleasure to introduce the speakers for our last topic today. Grace Pan is a partner at Kay Scholer in our New York office. She is a graduate of Northwestern University School of Law, where she graduated Phi Delta Phi and Iota Sigma Phi. Grace speaks Chinese and Japanese, travels often to Asia, and represents numerous Asian clients with intellectual property and commercial issues. Grace is a member of numerous professional ...

Recorded on: Apr. 2, 2013

DAVID BARR: Good afternoon everyone. Welcome back for the afternoon session of our conference. And I'm pleased to introduce Joe Drayton from Cooley, who's going to be speaking about the American Invents Act, post-grant procedures under the AIA. Joe Drayton is a partner in Cooley's litigation department. And he's a member of their intellectual property litigation practice group. He joined Cooley in 2012. And he's a resident in Cooley's New York office. ...

Recorded on: Apr. 2, 2013

DANIEL REISNER: I'd like to introduce our next speaker, Steve Elliott. He has an undergraduate degree in chemical engineering from MIT. He was then a process and materials engineer for Intel Corporation, where he developed integrated circuit manufacturing technology. Now Steve is a special counsel at Sullivan & Cromwell, where he represents clients in a wide range of technologies, including pharmaceuticals, medical devices, biotechnology, and ...

Recorded on: Apr. 3, 2013

SCOTT MCKEOWN: Welcome back, everybody. We're ready to kick off the afternoon session. But before we do, we did have one question that came in late. And that question was, must an IPR petition be accompanied by an expert declaration? For example, the questioner wants to know if you have clear disclosures in the prior art, maybe you can just come in without the declaration. The short answer is of course there's no requirement that you file a declaration. ...

Recorded on: Apr. 3, 2013

SCOTT: Welcome back, everybody. We're going to get started so we can get everybody to lunch on time. So the next module is focusing on discovery, which is a new component of these PTAB mechanisms. There was, as we all learned recently thanks to the federal circuit case last week, there's certainly no discovery in inter partes reexamination. And that was pointed out by Congress, that patent owners, in particular, wanted to challenge some of these declarations ...